{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:25:52Z","timestamp":1787570752199,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2, like many viruses, generates syncytia but the role of syncytia formation in viral evolution remains unknown. Using SARS-CoV-2 and SARS-CoV-2 Spike (S) replacement vesicular stomatitis (VSV), we show that S-mediated syncytia impair the antiviral effects of interferons in cultured cells, human lung cell cultures, and hACE2 transgenic mice. Amino acid substitutions that modulate syncytia formation in Delta- and Omicron-encoded S have parallel effects on viral interferon resistance. S-mediated syncytia compromise antibody-mediated virus neutralization in cultured cells. We recapitulate interferon and neutralizing antibody resistance in syncytia generated by the orthoreovirus p14 fusion-associated small transmembrane (FAST) protein in VSV, influenza virus, and seasonal coronavirus OC43 infections. These findings explain selection of SARS-CoV-2 fusogenic variants in humans and, more generally, the evolution of fusogenic viruses driven by adaptive and innate immunity.<\/jats:p>","DOI":"10.1038\/s41467-026-74676-8","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:05:23Z","timestamp":1784559923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral syncytia evolve to resist interferon"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-7031","authenticated-orcid":false,"given":"Tiansheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-9494","authenticated-orcid":false,"given":"Chengjin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyo","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-5182","authenticated-orcid":false,"given":"Ivan","family":"Kosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1149-9324","authenticated-orcid":false,"given":"Jaroslav","family":"Holly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kosikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-4953","authenticated-orcid":false,"given":"Alex A.","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed F.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-5554","authenticated-orcid":false,"given":"Hang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3826-1906","authenticated-orcid":false,"given":"Jonathan W.","family":"Yewdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"74676_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2012.11.004","volume":"3","author":"P Zhong","year":"2013","unstructured":"Zhong, P., Agosto, L. M., Munro, J. B. & Mothes, W. Cell-to-cell transmission of viruses. Curr. Opin. Virol. 3, 44\u201350 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"74676_CR2","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1093\/emboj\/17.14.3899","volume":"17","author":"T Cathomen","year":"1998","unstructured":"Cathomen, T. et al. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J. 17, 3899\u20133908 (1998).","journal-title":"EMBO J."},{"key":"74676_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41586-021-04266-9","volume":"602","author":"A Saito","year":"2022","unstructured":"Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300\u2013306 (2022).","journal-title":"Nature"},{"key":"74676_CR4","doi-asserted-by":"crossref","unstructured":"Jo, W. K. et al. Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants. Proc. Natl. Acad. Sci. USA 118, e2026558118 (2021).","DOI":"10.1073\/pnas.2026558118"},{"key":"74676_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-4-89","volume":"4","author":"J Sterjovski","year":"2007","unstructured":"Sterjovski, J. et al. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4, 89 (2007).","journal-title":"Retrovirology"},{"key":"74676_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"74676_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41579-022-00841-7","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"74676_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol"},{"key":"74676_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-021-04342-0","volume":"602","author":"L Ulrich","year":"2022","unstructured":"Ulrich, L. et al. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. Nature 602, 307\u2013313 (2022).","journal-title":"Nature"},{"key":"74676_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.abi7994","volume":"373","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern. Science 373, 648\u2013654 (2021).","journal-title":"Science"},{"key":"74676_CR11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.abl8506","volume":"374","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science 374, 1621\u20131626 (2021).","journal-title":"Science"},{"key":"74676_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450\u2013452 (2020).","journal-title":"Nat. Med"},{"key":"74676_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41564-020-0771-4","volume":"5","author":"MF Boni","year":"2020","unstructured":"Boni, M. F. et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. 5, 1408\u20131417 (2020).","journal-title":"Nat. Microbiol"},{"key":"74676_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-020-0184-0","volume":"5","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct. Target Ther. 5, 92 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"74676_CR15","doi-asserted-by":"crossref","unstructured":"Zeng, C. et al. SARS-CoV-2 spreads through cell-to-cell transmission. Proc. Natl. Acad. Sci. USA 119, e2111400119 (2022).","DOI":"10.1073\/pnas.2111400119"},{"key":"74676_CR16","doi-asserted-by":"publisher","first-page":"e1009246","DOI":"10.1371\/journal.ppat.1009246","volume":"17","author":"G Papa","year":"2021","unstructured":"Papa, G. et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog. 17, e1009246 (2021).","journal-title":"PLoS Pathog."},{"key":"74676_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","volume":"594","author":"L Braga","year":"2021","unstructured":"Braga, L. et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 594, 88\u201393 (2021).","journal-title":"Nature"},{"key":"74676_CR18","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106267","volume":"39","author":"J Buchrieser","year":"2020","unstructured":"Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).","journal-title":"EMBO J."},{"key":"74676_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103104","volume":"61","author":"R Bussani","year":"2020","unstructured":"Bussani, R. et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine 61, 103104 (2020).","journal-title":"EBioMedicine"},{"key":"74676_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","volume":"591","author":"BA Johnson","year":"2021","unstructured":"Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293\u2013299 (2021).","journal-title":"Nature"},{"key":"74676_CR21","doi-asserted-by":"crossref","unstructured":"Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899\u2013909 (2021).","DOI":"10.1038\/s41564-021-00908-w"},{"key":"74676_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21213-4","volume":"12","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 12, 961 (2021).","journal-title":"Nat. Commun."},{"key":"74676_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34571-4","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. Nat. Commun. 13, 6792 (2022).","journal-title":"Nat. Commun."},{"key":"74676_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01415-21","volume":"12","author":"M Sasaki","year":"2021","unstructured":"Sasaki, M. et al. SARS-CoV-2 bearing a mutation at the S1\/S2 cleavage site exhibits attenuated virulence and confers protective immunity. mBio 12, e0141521 (2021).","journal-title":"mBio"},{"key":"74676_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/22221751.2020.1756700","volume":"9","author":"SY Lau","year":"2020","unstructured":"Lau, S. Y. et al. Attenuated SARS-CoV-2 variants with deletions at the S1\/S2 junction. Emerg. Microbes Infect. 9, 837\u2013842 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"74676_CR26","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020)."},{"key":"74676_CR27","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020)."},{"key":"74676_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","volume":"603","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., Bastard, P., Effort, C. H. G., Cobat, A. & Casanova, J. L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603, 587\u2013598 (2022).","journal-title":"Nature"},{"key":"74676_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nri888","volume":"2","author":"MG Katze","year":"2002","unstructured":"Katze, M. G., He, Y. & Gale, M. Jr Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2, 675\u2013687 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"74676_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28, 475\u2013485 e475 (2020).","journal-title":"Cell Host Microbe"},{"key":"74676_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.chom.2020.06.020","volume":"28","author":"ME Dieterle","year":"2020","unstructured":"Dieterle, M. E. et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe 28, 486\u2013496 e486 (2020).","journal-title":"Cell Host Microbe"},{"key":"74676_CR32","doi-asserted-by":"publisher","first-page":"e1009233","DOI":"10.1371\/journal.ppat.1009233","volume":"17","author":"M Sasaki","year":"2021","unstructured":"Sasaki, M. et al. SARS-CoV-2 variants with mutations at the S1\/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 17, e1009233 (2021).","journal-title":"PLoS Pathog."},{"key":"74676_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF01317496","volume":"60","author":"K Otsuki","year":"1979","unstructured":"Otsuki, K., Maeda, J., Yamamoto, H. & Tsubokura, M. Studies on avian infectious bronchitis virus (IBV). III. Interferon induction by and sensitivity to interferon of IBV. Arch. Virol. 60, 249\u2013255 (1979).","journal-title":"Arch. Virol."},{"key":"74676_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1099\/0022-1317-43-1-247","volume":"43","author":"JM Emeny","year":"1979","unstructured":"Emeny, J. M. & Morgan, M. J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43, 247\u2013252 (1979).","journal-title":"J. Gen. Virol."},{"key":"74676_CR35","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1021\/bi00640a030","volume":"16","author":"A Jimenez","year":"1977","unstructured":"Jimenez, A., Carrasco, L. & Vazquez, D. Enzymic and nonenzymic translocation by yeast polysomes. site of action of a number of inhibitors. Biochemistry 16, 4727\u20134730 (1977).","journal-title":"Biochemistry"},{"key":"74676_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1083\/jcb.201112145","volume":"197","author":"A David","year":"2012","unstructured":"David, A. et al. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J. Cell Biol. 197, 45\u201357 (2012).","journal-title":"J. Cell Biol."},{"key":"74676_CR37","doi-asserted-by":"crossref","unstructured":"Vanderheiden, A. et al. Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J. Virol. 94, e00985-20 (2020).","DOI":"10.1128\/JVI.00985-20"},{"key":"74676_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202370119","volume":"119","author":"G Beucher","year":"2022","unstructured":"Beucher, G. et al. Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction. Proc. Natl. Acad. Sci. USA 119, e2202370119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74676_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00130-21","volume":"95","author":"O Alfi","year":"2021","unstructured":"Alfi, O. et al. Human nasal and lung tissues infected ex vivo with SARS-CoV-2 provide insights into differential tissue-specific and virus-specific innate immune responses in the upper and lower respiratory tract. J. Virol. 95, e0013021 (2021).","journal-title":"J. Virol."},{"key":"74676_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110799","volume":"39","author":"Z Chong","year":"2022","unstructured":"Chong, Z. et al. Nasally delivered interferon-lambda protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Rep. 39, 110799 (2022).","journal-title":"Cell Rep."},{"key":"74676_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/v5030834","volume":"5","author":"F Sorgeloos","year":"2013","unstructured":"Sorgeloos, F., Kreit, M., Hermant, P., Lardinois, C. & Michiels, T. Antiviral type I and type III interferon responses in the central nervous system. Viruses 5, 834\u2013857 (2013).","journal-title":"Viruses"},{"key":"74676_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"74676_CR43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"74676_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9534","volume":"9","author":"I Kosik","year":"2024","unstructured":"Kosik, I. et al. C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire. Sci. Immunol. 9, eadj9534 (2024).","journal-title":"Sci. Immunol."},{"key":"74676_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","volume":"603","author":"R Suzuki","year":"2022","unstructured":"Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700\u2013705 (2022).","journal-title":"Nature"},{"key":"74676_CR46","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108944","volume":"40","author":"MM Rajah","year":"2021","unstructured":"Rajah, M. M. et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. EMBO J. 40, e108944 (2021).","journal-title":"EMBO J."},{"key":"74676_CR47","doi-asserted-by":"crossref","unstructured":"Chang, C. W. et al. A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the delta and omicron variants. Viruses 14, 1369 (2022).","DOI":"10.3390\/v14071369"},{"key":"74676_CR48","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18723","volume":"16","author":"P Teeranaipong","year":"2013","unstructured":"Teeranaipong, P. et al. Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay. J. Int AIDS Soc. 16, 18723 (2013).","journal-title":"J. Int AIDS Soc."},{"key":"74676_CR49","doi-asserted-by":"crossref","unstructured":"Lamers, M. M. et al. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation. Elife 10, e02168-20 (2021).","DOI":"10.7554\/eLife.66815"},{"key":"74676_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veac080","volume":"8","author":"V Hill","year":"2022","unstructured":"Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 8, veac080 (2022).","journal-title":"Virus Evol."},{"key":"74676_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"74676_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154\u2013162 e155 (2022).","journal-title":"Cell Host Microbe"},{"key":"74676_CR53","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 383, 2291\u20132293 (2020).","journal-title":"N. Engl. J. Med"},{"key":"74676_CR54","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1126\/science.acx9738","volume":"374","author":"K Kupferschmidt","year":"2021","unstructured":"Kupferschmidt, K. Where did \u2018weird\u2019 Omicron come from? Science 374, 1179 (2021).","journal-title":"Science"},{"key":"74676_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100943","volume":"4","author":"C Chaguza","year":"2023","unstructured":"Chaguza, C. et al. Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. Cell Rep. Med. 4, 100943 (2023).","journal-title":"Cell Rep. Med"},{"key":"74676_CR56","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. SARS-CoV-2 Variants in Patients with Immunosuppression. N. Engl. J. Med. 385, 562\u2013566 (2021).","journal-title":"N. Engl. J. Med"},{"key":"74676_CR57","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s42003-023-05081-w","volume":"6","author":"T Tamura","year":"2023","unstructured":"Tamura, T. et al. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5. Commun. Biol. 6, 772 (2023).","journal-title":"Commun. Biol."},{"key":"74676_CR58","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.chom.2022.10.003","volume":"30","author":"A Saito","year":"2022","unstructured":"Saito, A. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe 30, 1540\u20131555 e1515 (2022).","journal-title":"Cell Host Microbe"},{"key":"74676_CR59","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","volume":"185","author":"D Yamasoba","year":"2022","unstructured":"Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell 185, 2103\u20132115 e2119 (2022).","journal-title":"Cell"},{"key":"74676_CR60","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1016\/j.cell.2022.09.018","volume":"185","author":"I Kimura","year":"2022","unstructured":"Kimura, I. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell 185, 3992\u20134007 e3916 (2022).","journal-title":"Cell"},{"key":"74676_CR61","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.chom.2024.01.001","volume":"32","author":"T Tamura","year":"2024","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. Cell Host Microbe 32, 170\u2013180 e112 (2024).","journal-title":"Cell Host Microbe"},{"key":"74676_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-023-00631-2","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic recombinant EK1 peptide. Cell Discov. 10, 6 (2024).","journal-title":"Cell Discov."},{"key":"74676_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41564-024-01878-5","volume":"10","author":"W Furnon","year":"2025","unstructured":"Furnon, W. et al. Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic. Nat. Microbiol. 10, 77\u201393 (2025).","journal-title":"Nat. Microbiol"},{"key":"74676_CR64","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1038\/s41418-021-00782-3","volume":"28","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination. Cell Death Differ. 28, 2765\u20132777 (2021).","journal-title":"Cell Death Differ."},{"key":"74676_CR65","doi-asserted-by":"crossref","unstructured":"Sanders, D. W. et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. Elife 10, e65962 (2021).","DOI":"10.7554\/eLife.65962"},{"key":"74676_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/biot.201400821","volume":"10","author":"E Kowarz","year":"2015","unstructured":"Kowarz, E., Loscher, D. & Marschalek, R. Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. Biotechnol. J. 10, 647\u2013653 (2015).","journal-title":"Biotechnol. J."},{"key":"74676_CR67","doi-asserted-by":"crossref","unstructured":"Ye, C. et al. Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. mBio 11, e02168-20 (2020).","DOI":"10.1128\/mBio.02168-20"},{"key":"74676_CR68","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","volume":"92","author":"ND Lawson","year":"1995","unstructured":"Lawson, N. D., Stillman, E. A., Whitt, M. A. & Rose, J. K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92, 4477\u20134481 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74676_CR69","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato, V. A. et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183, 1901\u20131912 e1909 (2020).","journal-title":"Cell"},{"key":"74676_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"74676_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26803-w","volume":"12","author":"P Radvak","year":"2021","unstructured":"Radvak, P. et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat. Commun. 12, 6559 (2021).","journal-title":"Nat. Commun."},{"key":"74676_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105507","volume":"25","author":"HJ Kwon","year":"2022","unstructured":"Kwon, H. J. et al. Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. iScience 25, 105507 (2022).","journal-title":"iScience"},{"key":"74676_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28673","volume":"95","author":"HJ Kwon","year":"2023","unstructured":"Kwon, H. J. et al. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2. J. Med. Virol. 95, e28673 (2023).","journal-title":"J. Med. Virol."},{"key":"74676_CR74","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41594-023-01023-6","volume":"30","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein. Nat. Struct. Mol. Biol. 30, 980\u2013990 (2023).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74676_CR75","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085 e1012 (2020).","journal-title":"Cell"},{"key":"74676_CR76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-022-04630-3","volume":"605","author":"LR Wong","year":"2022","unstructured":"Wong, L. R. et al. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146\u2013151 (2022).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74676-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74676-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:04:08Z","timestamp":1787569448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74676-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74676"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74676-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3846435\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8851"}}